secwatch.observer — SEC 8-K summary
======================================

Issuer:     Benitec Biopharma Inc. (BNTC)
CIK:        0001808898
Form:       8-K
Filed at:   2026-02-12T23:59:59+00:00
Accession:  0001193125-26-047742
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Benitec Q2 FY2026 net loss $11.8M; all Cohort 1 patients respond to BB-301 at 12 months
--------------------------------------------------------------------------------

- Net loss of $11.8M ($0.26 per share) vs $9.6M YoY; total expenses $13.4M (up from $10.8M).
- All 4 Cohort 1 completers in BB-301 Phase 1b/2a met Responder criteria at 12-month follow-up.
- Patient 1 showed deepening improvements in swallow function and dysphagia at 24 months.
- Cash and equivalents $189M; FDA meeting mid-2026 to confirm pivotal study design for BB-301.
- Cohort 2 interim results expected mid-2026; first patient dosed in Q4 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808898/000119312526047742/0001193125-26-047742-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808898/000119312526047742/bntc-20260212.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-047742

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer